Financial Summary (All financials)
| In millions of CNY, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 2,838.2 | 3,585.4 | 2,809.4 | 2,022.3 |
| Revenue growth | -20.8% | 27.6% | 38.9% | |
| Cost of goods sold | 556.9 | 557.2 | 430.8 | 292.5 |
| Gross profit | 2,281.3 | 3,028.2 | 2,378.6 | 1,729.8 |
| Gross margin | 80.4% | 84.5% | 84.7% | 85.5% |
| Sales and marketing | 2,712.3 | 2,951.0 | 2,121.0 | 1,362.2 |
| Research and development | 90.7 | 93.9 | 70.9 | 65.5 |
| General and administrative | 112.4 | 119.0 | 79.6 | 82.4 |
| EBIT | -621.2 | -109.0 | 131.8 | 232.1 |
| EBIT margin | -21.9% | -3.0% | 4.7% | 11.5% |
| Pre-tax income | -596.8 | -124.6 | 94.0 | 212.4 |
| Income taxes | 114.5 | 0.0 | 18.6 | 45.8 |
| Tax rate | | 0.0% | 19.8% | 21.6% |
| Net income | -711.2 | -4,958.4 | -3,130.9 | -264.5 |
| Net margin | -25.1% | -138.3% | -111.4% | -13.1% |
| |
| Diluted EPS | ($1.37) | ($12.20) | ($57.44) | ($7.61) |
| Shares outstanding (diluted) | 518.3 | 406.6 | 54.5 | 34.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|